Celldex Therapeutics reported $66.55M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Agenus USD 35.32M 2.51M Dec/2025
Amgen USD 539M 1000K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Celldex Therapeutics USD 66.55M 102K Dec/2025
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Northwest Biotherapeutics USD 1.52B 1.52B Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Rigel Pharmaceuticals USD 17K 158K Jun/2024
Roche Holding CHF 795.62M 699.54K Dec/2025